PEG Linker Drug Loading and Pharmacokinetic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Antibody-Drug Conjugates (ADCs) face challenges with high drug loading capacity leading to rapid clearance and reduced therapeutic window, along with issues of hydrophobic linker aggregation and drug resistance, which affect their efficacy and toxicity.
Innovation Solution
A PEG linker with uniformly distributed linking sites is used to create a ligand drug conjugate, masking hydrophobicity and allowing for higher drug loading while maintaining pharmacokinetic characteristics, thereby reducing toxicity and enhancing therapeutic window.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high drug loading capacity is used in ADC, then the amount of drug delivered to target cells is increased, but the conjugate is rapidly cleared and therapeutic window is reduced
Solution Approach 1:
The patent changes the chemical parameters of the linker by using PEG (polyethylene glycol) with specific molecular weights (2000-5000 Da) and incorporating hydrophilic amino acid residues. This parameter change makes the linker more hydrophilic, which prevents aggregation and improves pharmacokinetic stability while maintaining high drug loading capacity (2-8 drugs per antibody).
Solution Approach 2:
The patent creates a composite linker structure combining PEG chains with hydrophilic amino acid residues (such as lysine, arginine, histidine, or a combination thereof). This composite material approach integrates the hydrophilic properties of both PEG and amino acids to achieve optimal balance between drug loading and pharmacokinetic stability.
2Productivity
If hydrophobic linker is used to deliver cytotoxic drugs, then the drug delivery efficiency is improved, but aggregation of conjugate occurs and affinity of antibody is reduced
Solution Approach 1:
The patent fundamentally changes the hydrophobicity parameter of the linker by selecting PEG as the backbone and incorporating hydrophilic amino acid residues. This parameter change ensures the linker remains hydrophilic even at high drug loading capacities, preventing aggregation while maintaining delivery efficiency through the PEG chain's solubility characteristics.
3Quantity of substance
If high drug loading capacity is used, then the concentration of toxin delivered to target cells is increased, but toxicity to individual increases due to drug release
Solution Approach 1:
The patent changes the chemical environment around the drug molecules by using a hydrophilic PEG linker with amino acid residues. This creates a more favorable solvation shell that stabilizes the drug-conjugate complex and reduces spontaneous drug release, thereby maintaining high toxin concentration at the target site while reducing off-target toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PEG linker enables high drug loading capacity with low toxicity and improved pharmacokinetic profiles, preventing hydrophobic aggregation and enhancing the therapeutic efficacy of the ligand drug conjugate.
Implementation Method 1
By using a PEG linker in a ligand drug conjugate, the present invention is capable of masking the hydrophobicity of the drug or conjugate
Implementation Method 2
avoiding the problem of reduced pharmaceutical efficacy caused by hydrophobic aggregation brought by local dense distribution of drugs
Data Source
AI summary
A PEG linker as represented by formula (I), wherein n and m are respectively an integer from 1 to 7, providing the PEG linker with 1 to 49 linking sites. A ligand drug conjugate as represented by formula (II). The conjugate uses the PEG linker to increase a drug loading capacity and drug loading diversity, thereby improving pharmaceutical efficacy.Y1-PEG1-{R1-PEG2-{Y4}n}m (I)TM-{R2-PEG1-{R1-PEG2-{R3-A′-drug}n}m}l (II)